Cartesian Therapeutics Net Income
| RNAC Stock | 7.48 0.12 1.58% |
As of the 5th of March, Cartesian Therapeutics shows the Downside Deviation of 4.63, risk adjusted performance of 0.0316, and Mean Deviation of 3.57. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Cartesian Therapeutics, as well as the relationship between them.
Cartesian Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 61.2708 | Revenue | Earnings Share (1.33) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -69.7 M | -73.2 M | |
| Net Income Applicable To Common Shares | 40.7 M | 42.7 M | |
| Net Loss | -69.7 M | -73.2 M | |
| Net Loss | (2.69) | (2.82) | |
| Net Income Per E B T | 1.15 | 1.54 |
Cartesian | Net Income | Build AI portfolio with Cartesian Stock |
Analyzing Cartesian Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Cartesian Therapeutics's current valuation and future prospects.
Latest Cartesian Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Cartesian Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cartesian Therapeutics financial statement analysis. It represents the amount of money remaining after all of Cartesian Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cartesian Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cartesian Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (77.42 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cartesian Net Income Regression Statistics
| Arithmetic Mean | (47,703,311) | |
| Geometric Mean | 36,789,773 | |
| Coefficient Of Variation | (113.40) | |
| Mean Deviation | 36,851,505 | |
| Median | (36,210,000) | |
| Standard Deviation | 54,094,487 | |
| Sample Variance | 2926.2T | |
| Range | 255.1M | |
| R-Value | (0.50) | |
| Mean Square Error | 2355.3T | |
| R-Squared | 0.25 | |
| Significance | 0.04 | |
| Slope | (5,306,801) | |
| Total Sum of Squares | 46819.4T |
Cartesian Net Income History
Other Fundumenentals of Cartesian Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Cartesian Therapeutics Net Income component correlations
Cartesian Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cartesian Therapeutics is extremely important. It helps to project a fair market value of Cartesian Stock properly, considering its historical fundamentals such as Net Income. Since Cartesian Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cartesian Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cartesian Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Cartesian diversify its offerings? Factors like these will boost the valuation of Cartesian Therapeutics. Anticipated expansion of Cartesian directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cartesian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.07) | Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth 0.168 | Return On Assets |
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Cartesian Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cartesian Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cartesian Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cartesian Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cartesian Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cartesian Therapeutics.
| 12/05/2025 |
| 03/05/2026 |
If you would invest 0.00 in Cartesian Therapeutics on December 5, 2025 and sell it all today you would earn a total of 0.00 from holding Cartesian Therapeutics or generate 0.0% return on investment in Cartesian Therapeutics over 90 days. Cartesian Therapeutics is related to or competes with Eupraxia Pharmaceuticals, Inventiva, Nautilus Biotechnology, Orchestra BioMed, Mediwound, Aardvark Therapeutics, and Fennec Pharmaceuticals. Cartesian Therapeutics is entity of United States More
Cartesian Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cartesian Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cartesian Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.63 | |||
| Information Ratio | 0.0218 | |||
| Maximum Drawdown | 28.9 | |||
| Value At Risk | (8.19) | |||
| Potential Upside | 7.64 |
Cartesian Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cartesian Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cartesian Therapeutics' standard deviation. In reality, there are many statistical measures that can use Cartesian Therapeutics historical prices to predict the future Cartesian Therapeutics' volatility.| Risk Adjusted Performance | 0.0316 | |||
| Jensen Alpha | 0.145 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.0232 | |||
| Treynor Ratio | (1.49) |
Cartesian Therapeutics March 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0316 | |||
| Market Risk Adjusted Performance | (1.48) | |||
| Mean Deviation | 3.57 | |||
| Semi Deviation | 4.48 | |||
| Downside Deviation | 4.63 | |||
| Coefficient Of Variation | 3253.01 | |||
| Standard Deviation | 4.93 | |||
| Variance | 24.35 | |||
| Information Ratio | 0.0218 | |||
| Jensen Alpha | 0.145 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.0232 | |||
| Treynor Ratio | (1.49) | |||
| Maximum Drawdown | 28.9 | |||
| Value At Risk | (8.19) | |||
| Potential Upside | 7.64 | |||
| Downside Variance | 21.41 | |||
| Semi Variance | 20.04 | |||
| Expected Short fall | (3.95) | |||
| Skewness | 0.3559 | |||
| Kurtosis | 1.78 |
Cartesian Therapeutics Backtested Returns
Cartesian Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Cartesian Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0522, which signifies that the company had a 0.0522 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Cartesian Therapeutics, which you can use to evaluate the volatility of the firm. Please makes use of Cartesian Therapeutics' Risk Adjusted Performance of 0.0316, downside deviation of 4.63, and Mean Deviation of 3.57 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Cartesian Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of -0.0953, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Cartesian Therapeutics are expected to decrease at a much lower rate. During the bear market, Cartesian Therapeutics is likely to outperform the market. Please check Cartesian Therapeutics' skewness, day typical price, and the relationship between the downside variance and daily balance of power , to make a quick decision on whether Cartesian Therapeutics' price patterns will revert.
Auto-correlation | 0.47 |
Average predictability
Cartesian Therapeutics has average predictability. Overlapping area represents the amount of predictability between Cartesian Therapeutics time series from 5th of December 2025 to 19th of January 2026 and 19th of January 2026 to 5th of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cartesian Therapeutics price movement. The serial correlation of 0.47 indicates that about 47.0% of current Cartesian Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.47 | |
| Spearman Rank Test | 0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.27 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cartesian Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cartesian Therapeutics reported net income of (77.42 Million). This is 122.69% lower than that of the Biotechnology sector and 210.53% lower than that of the Health Care industry. The net income for all United States stocks is 113.56% higher than that of the company.
Cartesian Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cartesian Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cartesian Therapeutics could also be used in its relative valuation, which is a method of valuing Cartesian Therapeutics by comparing valuation metrics of similar companies.Cartesian Therapeutics is currently under evaluation in net income category among its peers.
Cartesian Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cartesian Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cartesian Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Cartesian Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Cartesian Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Cartesian Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cartesian Therapeutics' value.| Shares | Two Sigma Investments Llc | 2025-12-31 | 91.3 K | Marshall Wace Asset Management Ltd | 2025-09-30 | 84.8 K | Gsa Capital Partners Llp | 2025-12-31 | 77.2 K | Citadel Advisors Llc | 2025-09-30 | 70.5 K | Walleye Trading Advisors, Llc | 2025-12-31 | 43.9 K | Renaissance Technologies Corp | 2025-12-31 | 41.1 K | Royal Bank Of Canada | 2025-09-30 | 36.2 K | Xtx Topco Ltd | 2025-09-30 | 26.3 K | Freestone Capital Holdings, Llc | 2025-09-30 | 25.9 K | Fmr Inc | 2025-12-31 | 1.4 M | Blackrock Inc | 2025-09-30 | 649.3 K |
Cartesian Fundamentals
| Return On Equity | -70.29 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (46.61) % | ||||
| Current Valuation | 66.85 M | ||||
| Shares Outstanding | 26 M | ||||
| Shares Owned By Insiders | 60.75 % | ||||
| Shares Owned By Institutions | 20.00 % | ||||
| Number Of Shares Shorted | 2.22 M | ||||
| Price To Book | 31.26 X | ||||
| Price To Sales | 178.28 X | ||||
| Revenue | 38.91 M | ||||
| Gross Profit | (51.76 M) | ||||
| EBITDA | (75.99 M) | ||||
| Net Income | (77.42 M) | ||||
| Cash And Equivalents | 106.44 M | ||||
| Total Debt | 13.98 M | ||||
| Book Value Per Share | (1.38) X | ||||
| Cash Flow From Operations | (23.67 M) | ||||
| Short Ratio | 23.31 X | ||||
| Earnings Per Share | (1.33) X | ||||
| Target Price | 35.57 | ||||
| Number Of Employees | 66 | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 194.51 M | ||||
| Total Asset | 435.02 M | ||||
| Retained Earnings | (692.07 M) | ||||
| Working Capital | 193.65 M | ||||
| Net Asset | 435.02 M |
About Cartesian Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cartesian Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cartesian Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cartesian Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cartesian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cartesian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cartesian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cartesian Therapeutics Stock:Check out For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Will Biotechnology sector continue expanding? Could Cartesian diversify its offerings? Factors like these will boost the valuation of Cartesian Therapeutics. Anticipated expansion of Cartesian directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cartesian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.07) | Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth 0.168 | Return On Assets |
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Cartesian Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cartesian Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cartesian Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.